Ritedose Now Offers the Largest Nebulized Drug Portfolio in the U.S.: FDA Approves the Company to Manufacture Generic Tobramycin Inhalation Solution

- Generic Tobramycin Inhalation Solution marks the first cystic fibrosis (CF) product in the Company’s portfolio
-Antibiotic is primarily used for chronic Pseudomonas aeruginosa infections in patients with CF

COLUMBIA, S.C., Oct. 30, 2025 (GLOBE NEWSWIRE) -- The Ritedose Corporation (Ritedose) announced that the U.S. Food and Drug Administration (FDA) approved its manufacturing and distribution of Tobramycin Inhalation Solution to treat patients six years and older with infections of Pseudomonas aeruginosa, a common bacterial infection among cystic fibrosis patients.

Tobramycin will be marketed by Ritedose Pharmaceuticals, the generics division of Ritedose (the largest sterile contract development manufacturing organization (CDMO) in the U.S., specializing in aseptic unit-dose medication production using Blow-Fill-Seal (BFS) technology). Ritedose licensed the drug’s Abbreviated New Drug Application (ANDA) from Hikma Pharmaceuticals.

“With the addition of Tobramycin, Ritedose now provides the largest nebulized drug portfolio in the country,” said CEO of Ritedose Jody Chastain. “Our recent investments in expanded facilities, cold chain processes and an additional packaging line have given us unparalleled capabilities in sterile manufacturing.”

Tobramycin is an aminoglycoside antibiotic indicated for the treatment of serious bacterial infections, including Pseudomonas aeruginosa (P.aeruginosa), in adults and pediatric patients six years of age and older. The Ritedose formulation is preservative-free and packaged as 300 mg doses in 5 ml ampules, to be administered through a nebulizer device. The medication is now available for purchase.

“Now with Tobramycin in our portfolio, we can provide affordable, safe and reliable medications to patients with serious bacterial infections, expanding access to this critical therapy,” continued Chastain. “We’re also proud to strengthen supply chain resilience with the addition of a broad-spectrum antibiotic that is produced here in the United States.”

Tobramycin Inhalation Solution is the third generic drug announced by Ritedose this year. In April, Ritedose Pharmaceuticals received approval to manufacture generic Formoterol Fumarate Inhalation Solution for the maintenance treatment of chronic obstructive pulmonary disease (COPD). In March, Ritedose received approval for Albuterol Sulfate Inhalation Solution, 0.5% (2.5 mg/0.5 mL)*, for patients over 12 years of age suffering from acute attacks of bronchospasms or reversible obstructive airway disease. The addition rounded out Ritedose’s complete portfolio of albuterol treatments and addressed a nationwide shortage of the essential drug.

*Potency expressed as albuterol, equivalent to 3 mg of albuterol sulfate.

About The Ritedose Corporation

Ritedose is the largest sterile contract development manufacturing organization (CDMO) in the US specializing in sterile Blow Fill Seal (BFS) technology that ensures sterile, consistent, and safe unit dose delivery. The company’s process guides the development of molecules from clinical trials to commercialization of branded and generic inhalation and ophthalmic medications. With a focus on quality, innovation, and customer satisfaction, Ritedose partners with leading pharmaceutical companies to deliver safe, effective, and reliable medications that improve patient outcomes. Ritedose: Passion and Precision with a Purpose. For more information visit Ritedose.com

Media Contact:

Alex Keown
630-346-5141
akeown@inspire-agency.com
On Behalf of Ritedose

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/39b2ff09-2585-4764-93e1-4dd9766dc9fc

Ritedose receives FDA approval for Tobramycin

Tobramycin expands nation's largest nebulized drug portfolio.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.